STAT3

Signal transducer and activator of transcription 3 · P40763 · STAT3 on Sugi Atlas →

153,567 patent compounds predicted against STAT3, 101,327 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Andrographolide Andrographolide (SCHEMBL62262) 0.72 13/20
Andrographolide Andrographolide (SCHEMBL62263) 0.72 13/20
Nitazoxanide Nitazoxanide (SCHEMBL40981) 1.00 8/20
SCHEMBL159312 SCHEMBL159312 0.82 8/20
Tenonitrozole Tenonitrozole (SCHEMBL150446) 0.62 8/20
Gentiopicroside Gentiopicroside (SCHEMBL154304) 0.58 8/20
SCHEMBL45614 SCHEMBL45614 0.62 6/20
SCHEMBL45662 SCHEMBL45662 0.61 6/20
SCHEMBL45742 SCHEMBL45742 0.58 6/20
SCHEMBL184198 SCHEMBL184198 0.49 6/20
SCHEMBL124603 SCHEMBL124603 0.41 6/20
SCHEMBL124604 SCHEMBL124604 0.41 6/20
SCHEMBL45695 SCHEMBL45695 0.56 5/20
SCHEMBL45638 SCHEMBL45638 0.53 5/20
Simmondsin Simmondsin (SCHEMBL161237) 0.37 5/20
Nithiamide Nithiamide (SCHEMBL158858) 0.59 4/20
SCHEMBL140425 SCHEMBL140425 0.59 4/20
SCHEMBL76774 SCHEMBL76774 0.58 4/20
SCHEMBL30422 SCHEMBL30422 0.57 4/20
SCHEMBL28705 SCHEMBL28705 0.56 4/20

Clinical trials — most relevant to STAT3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial PHASE2/PHASE3UNKNOWN
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi. PHASE3COMPLETED
Ruxolitinib in Estrogen Receptor Positive Breast Cancer PHASE2COMPLETED
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia PHASE2COMPLETED
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation PHASE1/PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Itacitinib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients PHASE1RECRUITING
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers PHASE1COMPLETED
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis PHASE1COMPLETED
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer PHASE1COMPLETED
Immune Interactions in Severe Asthma nanCOMPLETED
Cutaneous JAK in Vitiligo and Acne Vulgaris. nanUNKNOWN
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts nanCOMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF nanNOT_YET_RECRUITING
Androgenetic Alopecia and the JAK-STAT Pathway nanCOMPLETED
Short-Term Application of Tocilizumab Following Myocardial Infarction nanCOMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
Prospective Observational Study Evaluating the Safety and Efficacy of Immunomodulatory Therapies in Refractory Inflammatory and Autoimmune Diseases nanNOT_YET_RECRUITING
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation nanCOMPLETED
Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C nanCOMPLETED
STAT4 in Multiple Sclerosis by PCR and Flow Cytometry nanCOMPLETED
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
The Role of Serum Cytokines IL_17 A and IL_10 in Disease Activity of Acute B Lymphoblastic Leukemia in South Egypt nanNOT_YET_RECRUITING
Deep Phenotyping of Cutaneous Lupus Erythematosus nanUNKNOWN
Regulation of the Immune System in Response to the Treatment With Tocilizumab in Rheumatoid Arthritis Patients nanCOMPLETED
Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study nanWITHDRAWN
The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a STAT3 binder may also engage these)

ProteinNameSimilarity
P42227 1.000 P42227 →
P61635 1.000 P61635 →
P52631 1.000 P52631 →
Q6DV79 1.000 Q6DV79 →
Q9PVX8 1.000 Q9PVX8 →
Q19S50 1.000 Q19S50 →
Q7ZXK3 1.000 Q7ZXK3 →
STAT1 Signal transducer and activator of transcription 1-alpha/beta 0.998 landscape →
Q764M5 0.997 Q764M5 →
P42225 0.991 P42225 →
P42231 0.982 P42231 →
Q62771 0.981 Q62771 →
Q8IWV8 0.980 Q8IWV8 →
Q9TUZ1 0.979 Q9TUZ1 →
Q8BIK4 0.978 Q8BIK4 →
Q8IZD9 0.978 Q8IZD9 →
Q9BZ29 0.976 Q9BZ29 →
G3V7Q0 0.975 G3V7Q0 →
STAT5A Signal transducer and activator of transcription 5A 0.975 landscape →
Q7TPD0 0.974 Q7TPD0 →
Q8CIQ7 0.974 Q8CIQ7 →
Q9R1D7 0.974 Q9R1D7 →
P42230 0.974 P42230 →
Q6IQ26 0.974 Q6IQ26 →
Q6PAL8 0.974 Q6PAL8 →
STAT6 Signal transducer and activator of transcription 6 0.973 landscape →
P52633 0.973 P52633 →
P52632 0.971 P52632 →
Q68E01 0.971 Q68E01 →
Q1LVW0 0.971 Q1LVW0 →